Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

James E. Flynn’s Deerfield Management Reveals Passive Stake in Amphastar Pharmaceuticals Inc. (AMPH)

James E. Flynn, the manager of Deerfield Management, has disclosed a new passive stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). Mr. Flynn owns 1.83 million shares of the company, equivalent to 4.22% of common stock, a new filing with the U.S. Securities and Exchange Commission showed.

Amphastar logo

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a specialty pharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and inhalation products. Recently, the company conducted a public offering in which it issued 8.0 million shares of its common stock, including 3.36 million shares from the selling stockholders. The offering was priced at $7.00 per share for a total offering amount of $56 million, according to a press release.

The underwriters were granted a 30-day option to purchase up to an additional 1.20 million shares of common stock. The underwriters exercised in full their option to purchase from the company all these additional shares of common stock at the initial public offering price of $7.00 per share. Including the exercise of the over-allotment option, the company has sold a total of 5.84 million shares of its common stock.

Deerfield Management is a healthcare focused investment firm specializing in funding R&D, managing hostile takeovers, corporate transitions and financial advisory services. The fund oversees $3.5 billion in assets. At the end of April, Deerfield reported a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP), owning nearly 660,000 shares. In addition, the fund revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV), holding around 1.70 million shares from 632,700 shares.

Also, in the month of April, Deerfield increased its stake in Insmed Incorporated (NASDAQ:INSM) to 3.04 million shares, equal to 7.75% of the company’s common shares.

Disclosure: none

Loading Comments...